Plant ID: NPO29146
Plant Latin Name: Polygonatum kingianum
Taxonomy Genus: Polygonatum
Taxonomy Family: Asparagaceae
NCBI TaxonomyDB:
261420
Plant-of-the-World-Online:
n.a.
Antiseptic; Vasodilator
China
TSHR; | |
CA12; | |
AKR1B1; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.320E-10 | 1.015E-05 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.571E-10 | 1.015E-05 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.786E-09 | 1.297E-05 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.024E-08 | 5.575E-05 | CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.782E-08 | 7.761E-05 | AKR1B1, CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.262E-07 | 3.924E-04 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 2.723E-07 | 6.588E-04 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.093E-07 | 6.735E-04 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.002E-07 | 1.634E-03 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 1.659E-06 | 2.779E-03 | AKR1B1, CYP19A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.743E-06 | 9.177E-03 | CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.886E-06 | 1.086E-02 | CYP2C9, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 3.081E-04 | 1.597E-01 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.702E-02 | 1.000E+00 | CYP2C19, CYP2C9, CYP3A4, LMNA |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.527E-07 | 3.971E-06 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.174E-06 | 2.826E-05 | CYP2C9, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.665E-06 | 3.177E-05 | CYP2C9, CYP3A4, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.329E-05 | 2.814E-04 | CYP2C9, AKR1B1, CYP2C19, CYP3A4, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.616E-04 | 1.068E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.289E-04 | 1.068E-03 | CYP3A4, CYP19A1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.876E-04 | 1.068E-03 | CYP2C9, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.627E-04 | 1.179E-03 | CYP2C9, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.513E-04 | 2.459E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.781E-03 | 1.763E-02 | CA12 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |